GATA2 and myelodysplastic syndrome: Further, patients with germline missense GATA2 mutations have a mean onset of MDS/AML at age 40 (81, 82), suggesting that these mutations do not directly cause myeloid malignancies; inactivation of the second GATA2 allele (by mutation or epigenetic silencing) appears to be necessary for AML development (78).